Immunosuppression and immunomodulation of experimental models of systemic lupus erythematosus and antiphospholipid syndrome.
Shoenfeld
Y
Y
Department of Medicine B, Sheba Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Israel.
Krause
I
I
D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000276:immunology / Q000517:prevention & control*; D015704:CD4 Antigens / Q000276:immunology; D004195:Disease Models, Animal; D015525:Fatty Acids, Omega-3 / Q000008:administration & dosage / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D007167:Immunotherapy; D008180:Lupus Erythematosus, Systemic / Q000276:immunology / Q000517:prevention & control*; D008713:Methimazole / Q000627:therapeutic use; D051379:Mice; D008807:Mice, Inbred BALB C; D009752:Nutritional Status; D013629:Tamoxifen / Q000627:therapeutic use
D000906:Antibodies; D015704:CD4 Antigens; D015525:Fatty Acids, Omega-3; D013629:Tamoxifen; D008713:Methimazole